surmount-1 tirzepatide trial obesity without diabetes Effect of on Body Weight and Control in Adults With Type 1 Diabetes and Overweight or Early‐Onset Obesity and Tirzepatide Treatment:

The most frequent adverse events with tirzepatide were mild-to-moderate gastrointestinal-related effects, including nausea, diarrhoea and vomiting, with few events leading to treatment discontinuation (fewer than 5%)

Here are some of the potential risks of using compounded tirzepatide: If you are considering using compounded tirzepatide, it is important to talk to your doctor

To keep discomfort minimal, your doctor will slowly increase your dose using a conservative, monthly schedule

provision of research materials from Eli Lilly and Company and Weight Watchers

Ongoing Support: Shay provides ongoing support for nutrition, exercise, and lifestyle change to ensure success

Available from [Accessed 17 Dec 2023] Eli Lilly and Company 2023